Contact Person : Lisa Scimemi; Last Date for the submission of abstract : Not Available ; Description : Includes: Advances in NGS and other technologies, NGS-based assay development, targeted panels vs exome sequencing, FDA-approval of PCR- and NGS-based diagnostics, hot topics and controversies in cancer sequencing.